Cargando…

The PI3K-Akt-mTOR and Associated Signaling Pathways as Molecular Drivers of Immune-Mediated Inflammatory Skin Diseases: Update on Therapeutic Strategy Using Natural and Synthetic Compounds

The dysregulated phosphatidylinositol-3-kinase (PI3K)-Akt-mammalian target of rapamycin (mTOR) signaling pathway has been implicated in various immune-mediated inflammatory and hyperproliferative dermatoses such as acne, atopic dermatitis, alopecia, psoriasis, wounds, and vitiligo, and is associated...

Descripción completa

Detalles Bibliográficos
Autores principales: Roy, Tithi, Boateng, Samuel T., Uddin, Mohammad B., Banang-Mbeumi, Sergette, Yadav, Rajesh K., Bock, Chelsea R., Folahan, Joy T., Siwe-Noundou, Xavier, Walker, Anthony L., King, Judy A., Buerger, Claudia, Huang, Shile, Chamcheu, Jean Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297376/
https://www.ncbi.nlm.nih.gov/pubmed/37371141
http://dx.doi.org/10.3390/cells12121671
_version_ 1785063869251584000
author Roy, Tithi
Boateng, Samuel T.
Uddin, Mohammad B.
Banang-Mbeumi, Sergette
Yadav, Rajesh K.
Bock, Chelsea R.
Folahan, Joy T.
Siwe-Noundou, Xavier
Walker, Anthony L.
King, Judy A.
Buerger, Claudia
Huang, Shile
Chamcheu, Jean Christopher
author_facet Roy, Tithi
Boateng, Samuel T.
Uddin, Mohammad B.
Banang-Mbeumi, Sergette
Yadav, Rajesh K.
Bock, Chelsea R.
Folahan, Joy T.
Siwe-Noundou, Xavier
Walker, Anthony L.
King, Judy A.
Buerger, Claudia
Huang, Shile
Chamcheu, Jean Christopher
author_sort Roy, Tithi
collection PubMed
description The dysregulated phosphatidylinositol-3-kinase (PI3K)-Akt-mammalian target of rapamycin (mTOR) signaling pathway has been implicated in various immune-mediated inflammatory and hyperproliferative dermatoses such as acne, atopic dermatitis, alopecia, psoriasis, wounds, and vitiligo, and is associated with poor treatment outcomes. Improved comprehension of the consequences of the dysregulated PI3K/Akt/mTOR pathway in patients with inflammatory dermatoses has resulted in the development of novel therapeutic approaches. Nonetheless, more studies are necessary to validate the regulatory role of this pathway and to create more effective preventive and treatment methods for a wide range of inflammatory skin diseases. Several studies have revealed that certain natural products and synthetic compounds can obstruct the expression/activity of PI3K/Akt/mTOR, underscoring their potential in managing common and persistent skin inflammatory disorders. This review summarizes recent advances in understanding the role of the activated PI3K/Akt/mTOR pathway and associated components in immune-mediated inflammatory dermatoses and discusses the potential of bioactive natural products, synthetic scaffolds, and biologic agents in their prevention and treatment. However, further research is necessary to validate the regulatory role of this pathway and develop more effective therapies for inflammatory skin disorders.
format Online
Article
Text
id pubmed-10297376
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102973762023-06-28 The PI3K-Akt-mTOR and Associated Signaling Pathways as Molecular Drivers of Immune-Mediated Inflammatory Skin Diseases: Update on Therapeutic Strategy Using Natural and Synthetic Compounds Roy, Tithi Boateng, Samuel T. Uddin, Mohammad B. Banang-Mbeumi, Sergette Yadav, Rajesh K. Bock, Chelsea R. Folahan, Joy T. Siwe-Noundou, Xavier Walker, Anthony L. King, Judy A. Buerger, Claudia Huang, Shile Chamcheu, Jean Christopher Cells Review The dysregulated phosphatidylinositol-3-kinase (PI3K)-Akt-mammalian target of rapamycin (mTOR) signaling pathway has been implicated in various immune-mediated inflammatory and hyperproliferative dermatoses such as acne, atopic dermatitis, alopecia, psoriasis, wounds, and vitiligo, and is associated with poor treatment outcomes. Improved comprehension of the consequences of the dysregulated PI3K/Akt/mTOR pathway in patients with inflammatory dermatoses has resulted in the development of novel therapeutic approaches. Nonetheless, more studies are necessary to validate the regulatory role of this pathway and to create more effective preventive and treatment methods for a wide range of inflammatory skin diseases. Several studies have revealed that certain natural products and synthetic compounds can obstruct the expression/activity of PI3K/Akt/mTOR, underscoring their potential in managing common and persistent skin inflammatory disorders. This review summarizes recent advances in understanding the role of the activated PI3K/Akt/mTOR pathway and associated components in immune-mediated inflammatory dermatoses and discusses the potential of bioactive natural products, synthetic scaffolds, and biologic agents in their prevention and treatment. However, further research is necessary to validate the regulatory role of this pathway and develop more effective therapies for inflammatory skin disorders. MDPI 2023-06-20 /pmc/articles/PMC10297376/ /pubmed/37371141 http://dx.doi.org/10.3390/cells12121671 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Roy, Tithi
Boateng, Samuel T.
Uddin, Mohammad B.
Banang-Mbeumi, Sergette
Yadav, Rajesh K.
Bock, Chelsea R.
Folahan, Joy T.
Siwe-Noundou, Xavier
Walker, Anthony L.
King, Judy A.
Buerger, Claudia
Huang, Shile
Chamcheu, Jean Christopher
The PI3K-Akt-mTOR and Associated Signaling Pathways as Molecular Drivers of Immune-Mediated Inflammatory Skin Diseases: Update on Therapeutic Strategy Using Natural and Synthetic Compounds
title The PI3K-Akt-mTOR and Associated Signaling Pathways as Molecular Drivers of Immune-Mediated Inflammatory Skin Diseases: Update on Therapeutic Strategy Using Natural and Synthetic Compounds
title_full The PI3K-Akt-mTOR and Associated Signaling Pathways as Molecular Drivers of Immune-Mediated Inflammatory Skin Diseases: Update on Therapeutic Strategy Using Natural and Synthetic Compounds
title_fullStr The PI3K-Akt-mTOR and Associated Signaling Pathways as Molecular Drivers of Immune-Mediated Inflammatory Skin Diseases: Update on Therapeutic Strategy Using Natural and Synthetic Compounds
title_full_unstemmed The PI3K-Akt-mTOR and Associated Signaling Pathways as Molecular Drivers of Immune-Mediated Inflammatory Skin Diseases: Update on Therapeutic Strategy Using Natural and Synthetic Compounds
title_short The PI3K-Akt-mTOR and Associated Signaling Pathways as Molecular Drivers of Immune-Mediated Inflammatory Skin Diseases: Update on Therapeutic Strategy Using Natural and Synthetic Compounds
title_sort pi3k-akt-mtor and associated signaling pathways as molecular drivers of immune-mediated inflammatory skin diseases: update on therapeutic strategy using natural and synthetic compounds
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297376/
https://www.ncbi.nlm.nih.gov/pubmed/37371141
http://dx.doi.org/10.3390/cells12121671
work_keys_str_mv AT roytithi thepi3kaktmtorandassociatedsignalingpathwaysasmoleculardriversofimmunemediatedinflammatoryskindiseasesupdateontherapeuticstrategyusingnaturalandsyntheticcompounds
AT boatengsamuelt thepi3kaktmtorandassociatedsignalingpathwaysasmoleculardriversofimmunemediatedinflammatoryskindiseasesupdateontherapeuticstrategyusingnaturalandsyntheticcompounds
AT uddinmohammadb thepi3kaktmtorandassociatedsignalingpathwaysasmoleculardriversofimmunemediatedinflammatoryskindiseasesupdateontherapeuticstrategyusingnaturalandsyntheticcompounds
AT banangmbeumisergette thepi3kaktmtorandassociatedsignalingpathwaysasmoleculardriversofimmunemediatedinflammatoryskindiseasesupdateontherapeuticstrategyusingnaturalandsyntheticcompounds
AT yadavrajeshk thepi3kaktmtorandassociatedsignalingpathwaysasmoleculardriversofimmunemediatedinflammatoryskindiseasesupdateontherapeuticstrategyusingnaturalandsyntheticcompounds
AT bockchelsear thepi3kaktmtorandassociatedsignalingpathwaysasmoleculardriversofimmunemediatedinflammatoryskindiseasesupdateontherapeuticstrategyusingnaturalandsyntheticcompounds
AT folahanjoyt thepi3kaktmtorandassociatedsignalingpathwaysasmoleculardriversofimmunemediatedinflammatoryskindiseasesupdateontherapeuticstrategyusingnaturalandsyntheticcompounds
AT siwenoundouxavier thepi3kaktmtorandassociatedsignalingpathwaysasmoleculardriversofimmunemediatedinflammatoryskindiseasesupdateontherapeuticstrategyusingnaturalandsyntheticcompounds
AT walkeranthonyl thepi3kaktmtorandassociatedsignalingpathwaysasmoleculardriversofimmunemediatedinflammatoryskindiseasesupdateontherapeuticstrategyusingnaturalandsyntheticcompounds
AT kingjudya thepi3kaktmtorandassociatedsignalingpathwaysasmoleculardriversofimmunemediatedinflammatoryskindiseasesupdateontherapeuticstrategyusingnaturalandsyntheticcompounds
AT buergerclaudia thepi3kaktmtorandassociatedsignalingpathwaysasmoleculardriversofimmunemediatedinflammatoryskindiseasesupdateontherapeuticstrategyusingnaturalandsyntheticcompounds
AT huangshile thepi3kaktmtorandassociatedsignalingpathwaysasmoleculardriversofimmunemediatedinflammatoryskindiseasesupdateontherapeuticstrategyusingnaturalandsyntheticcompounds
AT chamcheujeanchristopher thepi3kaktmtorandassociatedsignalingpathwaysasmoleculardriversofimmunemediatedinflammatoryskindiseasesupdateontherapeuticstrategyusingnaturalandsyntheticcompounds
AT roytithi pi3kaktmtorandassociatedsignalingpathwaysasmoleculardriversofimmunemediatedinflammatoryskindiseasesupdateontherapeuticstrategyusingnaturalandsyntheticcompounds
AT boatengsamuelt pi3kaktmtorandassociatedsignalingpathwaysasmoleculardriversofimmunemediatedinflammatoryskindiseasesupdateontherapeuticstrategyusingnaturalandsyntheticcompounds
AT uddinmohammadb pi3kaktmtorandassociatedsignalingpathwaysasmoleculardriversofimmunemediatedinflammatoryskindiseasesupdateontherapeuticstrategyusingnaturalandsyntheticcompounds
AT banangmbeumisergette pi3kaktmtorandassociatedsignalingpathwaysasmoleculardriversofimmunemediatedinflammatoryskindiseasesupdateontherapeuticstrategyusingnaturalandsyntheticcompounds
AT yadavrajeshk pi3kaktmtorandassociatedsignalingpathwaysasmoleculardriversofimmunemediatedinflammatoryskindiseasesupdateontherapeuticstrategyusingnaturalandsyntheticcompounds
AT bockchelsear pi3kaktmtorandassociatedsignalingpathwaysasmoleculardriversofimmunemediatedinflammatoryskindiseasesupdateontherapeuticstrategyusingnaturalandsyntheticcompounds
AT folahanjoyt pi3kaktmtorandassociatedsignalingpathwaysasmoleculardriversofimmunemediatedinflammatoryskindiseasesupdateontherapeuticstrategyusingnaturalandsyntheticcompounds
AT siwenoundouxavier pi3kaktmtorandassociatedsignalingpathwaysasmoleculardriversofimmunemediatedinflammatoryskindiseasesupdateontherapeuticstrategyusingnaturalandsyntheticcompounds
AT walkeranthonyl pi3kaktmtorandassociatedsignalingpathwaysasmoleculardriversofimmunemediatedinflammatoryskindiseasesupdateontherapeuticstrategyusingnaturalandsyntheticcompounds
AT kingjudya pi3kaktmtorandassociatedsignalingpathwaysasmoleculardriversofimmunemediatedinflammatoryskindiseasesupdateontherapeuticstrategyusingnaturalandsyntheticcompounds
AT buergerclaudia pi3kaktmtorandassociatedsignalingpathwaysasmoleculardriversofimmunemediatedinflammatoryskindiseasesupdateontherapeuticstrategyusingnaturalandsyntheticcompounds
AT huangshile pi3kaktmtorandassociatedsignalingpathwaysasmoleculardriversofimmunemediatedinflammatoryskindiseasesupdateontherapeuticstrategyusingnaturalandsyntheticcompounds
AT chamcheujeanchristopher pi3kaktmtorandassociatedsignalingpathwaysasmoleculardriversofimmunemediatedinflammatoryskindiseasesupdateontherapeuticstrategyusingnaturalandsyntheticcompounds